3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2- dimethyl- 8- oxo- 3,4- dihydro- 2H,8H- pyrano(3,2- g)chromen- 3- yl- ester

has antineoplastic activity; structure in first source

Also Known As:

3-(3,4-dihydroxyphenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano(3,2-g)chromen-3-yl-ester; 3-(3,4-dihydroxyphenyl)acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano(3,2-g)chromen-3-yl ester; CGK062; DH-ADM-PCE cpd; JHL45 compound

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chung, Young-Hwa: 2 articles (01/2019 - 01/2012)
2.	Oh, Sangtaek: 2 articles (01/2019 - 01/2012)
3.	Hwang, Dae Youn: 1 article (01/2019)
4.	Kang, Ho Young: 1 article (01/2019)
5.	Kaowinn, Sirichat: 1 article (01/2019)
6.	Kim, Ji Eun: 1 article (01/2019)
7.	Koh, Sang Seok: 1 article (01/2019)
8.	Lee, Mi Rim: 1 article (01/2019)
9.	Moon, Jeong: 1 article (01/2019)
10.	Yoo, Ah Young: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "Furthermore, CGK062 treatment suppressed CUG2‑mediated tumor formation in nude mice. " 01/01/2012 - "Therefore, CGK062 has significant therapeutic potential for the treatment of CRT-positive cancers." 01/01/2012 - "Furthermore, treatment of nude mice bearing PC3 xenograft tumors with CGK062 at doses of 50 mg/kg and 100 mg/kg (i.p.) significantly suppressed tumor growth. " 01/01/2019 - "CGK062, a small chemical molecule, inhibits cancer upregulated gene 2‑induced oncogenesis through NEK2 and β‑catenin." 01/01/2019 - "Treatment with CGK062, a small chemical molecule, which promotes the phosphorylation of β‑catenin at Ser33/Ser37 through protein kinase C (PKC)α to induce its degradation, reduced β‑catenin levels and inhibited the CUG2‑induced features of malignant tumors, including increased cell migration, invasion and sphere formation. "
2.	Carcinogenesis 01/01/2019 - "CGK062, a small chemical molecule, inhibits cancer upregulated gene 2‑induced oncogenesis through NEK2 and β‑catenin."
3.	Lung Neoplasms (Lung Cancer) 01/01/2019 - "CGK062 may thus have potential for use as a therapeutic drug against CUG2‑overexpressing lung cancer cells."

Related Drugs and Biologics

1.	Catenins
2.	Cyclin D1
3.	Proteins (Proteins, Gene)